Nucleic acid mediated delivery of therapeutic agents
By complexing anthracycline antibiotics with nucleic acid fragments to form nanoparticles, the problems of low bioavailability and high toxicity of existing therapeutic agents are solved, and more efficient and safer cancer treatment effects are achieved.
Patent Information
- Application Number
- CN202411130242.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-06
- Filing Date
- 2020-09-04
- Publication Date
- 2024-11-26
AI Technical Summary
Existing DNA or RNA-associated or bound therapeutic agents are low in bioavailability due to their inherent chemical structure, partially insoluble, and soluble therapeutic agents can cause systemic toxicity and quickly remove them from the body. Existing nanocarrier delivery systems There are problems such as low drug load, high immunogenicity, poor treatment effect and high cost.
Nucleic acid fragments are used as biologically active nanocarriers, and are complexed with anthracycline antibiotics such as doxorubicin (DOX) to form DOX/nucleic acid nanoparticles. They are prepared through self-assembly technology to achieve higher drug loads and longer cycle times. , reduces systemic toxicity and simplifies the preparation process.
It improves the bioavailability and therapeutic effect of therapeutic agents, extends tumor survival, reduces systemic toxicity, simplifies the preparation and production process, and achieves safer and more effective cancer treatment.
Smart Images

Figure CN119015258A_ABST
Abstract
Description
[0001] This application claims priority under 35 U.S.C. §119 to provisional application No. 62 / 897,254, filed on September 6, 2019, the disclosure of which is incorporated herein by reference. Technical Field
[0002] The present disclosure provides nucleic acid-mediated delivery of therapeutic agents that can be associated or bound to DNA or RNA and uses thereof. Background Art
[0003] Therapeutics that can associate or bind to DNA or RNA have great potential in treating cancer and other diseases, but their inherent chemical structure makes them completely or partially insoluble, resulting in limited bioavailability. Some of these therapeutics, while soluble, can cause systemic toxicity and are often cleared from the body very quickly. SUMMARY OF THE INVENTION
[0005] The present invention provides a delivery platform for therapeutic agents that can be associated or combined with DNA or RNA, which is more effective than current formulations and further has advantages in production cost and ease of assembly. In the exemplary studies introduced in the present invention, a mixture of nucleic acid fragments of 50 to 2,000 nucleotides was used as a bioactive nanocarrier for the intercalating agent doxorubicin (DOX). It was found that DOX can be complexed with nucleic acid fragments in a quick and easy manner. This DOX / nucleic acid formulation is more monodisperse than the nucleic acid fragments themselves and improves the therapeutic window of DOX. As pointed out in the studies of the present invention, it is clear that the delivery of therapeutic agents that can be associated or combined with DNA or RNA can generally be improved by using the delivery platform disclosed in the present invention.
[0006] In a specific embodiment, the present disclosure provides a composition comprising one or more therapeutic compounds, which are complexed with nucleic acid fragments to form nanoparticles. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more therapeutic compounds are small molecules that can associate or bind to DNA or RNA. In another embodiment or a further embodiment of any of the preceding embodiments, the nucleic acid fragments are compounded with the one or more therapeutic compounds in a weight / weight ratio of 2:1 to 10:1. In another embodiment or a further embodiment of any of the preceding embodiments, the nucleic acid fragments are compounded with the one or more therapeutic compounds in a weight / weight ratio of 4:1 to 7:1. In another embodiment or a further embodiment of any of the preceding embodiments, the nucleic acid fragments are compounded with the one or more therapeutic compounds in a weight / weight ratio of about 6:1. In another embodiment or a further embodiment of any of the preceding embodiments, the size of the nanoparticles is 20nm to 200nm. In another embodiment or a further embodiment of any of the preceding embodiments, the size of the nanoparticles is 50nm to 100nm. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more therapeutic compounds include anthracyclines, anthracenediones, camptothecins, podophyllins, minor groove binders, bleomycins and / or actinomycin D. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more therapeutic compounds include aclarubicin, doxorubicin, daunorubicin, idarubicin, epirubicin, amrubicin, pirarubicin, pentarubicin and / or daurubicin. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more therapeutic compounds include doxorubicin. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more therapeutic compounds include mitoxantrone, topotecan, etoposide, teniposide, bleomycin, actinomycin D and / or duocarmycin A. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more nucleic acid fragments include ligands that target the nanoparticles to specific cells, tissues, organs or tumors. In another embodiment or a further embodiment of any of the preceding embodiments, the nucleic acid fragments include naturally occurring fragments of DNA, RNA and / or DNA-RNA hybrids. In another embodiment or a further embodiment of any of the preceding embodiments, the nucleic acid fragment comprises chemically synthesized DNA, RNA and / or DNA-RNA hybrids of different nucleotide lengths. In another embodiment or a further embodiment of any of the preceding embodiments, the RNA has been modified to replace the 2' ribose hydroxyl group with -O-alkyl or halide. In another embodiment or a further embodiment of any of the preceding embodiments, the nucleic acid fragment is a DNA fragment.In another embodiment or a further embodiment of any of the preceding embodiments, the DNA fragment is from salmon DNA. In another embodiment or a further embodiment of any of the preceding embodiments, the length of the nucleic acid fragment is 20nt to 10,000nt. In another embodiment or a further embodiment of any of the preceding embodiments, the length of the nucleic acid fragment is 50nt to 2,000nt. In another embodiment or a further embodiment of any of the preceding embodiments, the composition comprises nanoparticles of one or more therapeutic compounds complexed with DNA fragments of 50nt to 2,000nt in length. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more therapeutic compounds are selected from aclarubicin, doxorubicin, daunorubicin, idarubicin, epirubicin, amrubicin, pirarubicin, valrubicin and zorubicin. In another embodiment or a further embodiment of any of the preceding embodiments, the one or more therapeutic compounds are doxorubicin.
[0007] In a certain embodiment, the present disclosure also provides a pharmaceutical composition, which comprises the composition disclosed in the present invention and a pharmaceutically acceptable carrier, diluent and / or excipient. In a further embodiment, the pharmaceutical composition is formulated for parenteral delivery.
[0008] In a specific embodiment, the disclosure further provides a method for treating a cancer patient in need of treatment, comprising: administering an effective amount of the pharmaceutical composition disclosed in the present invention to a subject. In a further embodiment, the cancer is selected from acute lymphocytic leukemia, acute myeloid leukemia, osteosarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, liver cancer, kidney cancer, multiple myeloma, neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thymoma, thyroid cancer, transitional cell bladder cancer, uterine sarcoma, Wilms' tumor and Waldenstrom's macroglobulinemia.
[0009] In a certain embodiment, the present disclosure provides a human subject with a cancer in need of treatment, comprising: administering an effective amount of a composition disclosed in the present invention. In a further embodiment, the cancer is selected from acute lymphocytic leukemia, acute myeloid leukemia, osteosarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, liver cancer, kidney cancer, multiple myeloma, neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thymoma (thyomas), thyroid cancer, transitional cell bladder cancer, uterine sarcoma, Wilms' tumor and Waldenstrom's macroglobulinemia. In another embodiment or a further embodiment of any of the foregoing embodiments, the method further comprises administering one or more anticancer agents to the subject, the anticancer agent being selected from angiogenesis inhibitors, tyrosine kinase inhibitors, PARP inhibitors, alkylating agents, vinca alkaloids, anthracyclines, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, aromatase inhibitors, mTor inhibitors, retinoids and HDAC inhibitors. In another embodiment or a further embodiment of any of the preceding embodiments, the method further comprises administering to the subject one or more anticancer agents selected from mitoxantrone, topotecan, etoposide, teniposide, bleomycin, actinomycin D, and duocarmycin A.
[0010] The details of one or more embodiments of the present disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 It shows that DNA quenches DOX fluorescence at a ratio of 6:1 (w / w). The fluorescence spectra of DNA:DOX ratios between 1-100 were first measured (spectra in the upper figure), and then the fluorescence spectra of DNA:DOX ratios between 1-10 were measured (spectra in the lower figure). The excitation wavelength was 490nm. The loading and encapsulation efficiency were determined to be ~14% and ~88%, respectively. It was found in the study that the weight ratio of DNA to DOX was 6:1.
[0012] Figure 2 Transmission electron microscopy (TEM) images of DNA (top) or DOX / DNA (bottom) prepared in water are shown. DNA was added to DOX in a 6:1 w / w ratio. Time was allotted for self-assembly. In this particular case, water was added to the mixture and the solution was allowed to sit for an additional 30 minutes. Final [DNA] = 6 μg / mL, Final [DOX] = 1 μg / mL.
[0013] Figure 3TEM images of DNA (upper panel) and DOX / DNA nanoparticles (lower panel) are shown. Both DOX / DNA and DNA were prepared in PBS and then diluted in H2O for imaging. Final [DNA] = 6 μg / mL, final [DOX] = 1 μg / mL. The size of the DOX / DNA nanoparticles is approximately 70 nm.
[0014] Figure 4 TEM images of lyophilized reconstituted DOX / DNA are shown. Lower magnification (left column) and higher magnification (right column) of DOX / DNA are shown. DOX / DNA was prepared in PBS, diluted with H2O, lyophilized overnight, then reconstituted with H2O and subsequently imaged. Final [DNA] = 6 g / mL, Final [DOX] = 1 μg / mL.
[0015] Figure 5 Another set of DOX / DNA TEM images reconstituted by lyophilization is shown. Lower magnification (left panel) and higher magnification (right panel) of DOX / DNA are shown. Final [DNA] = 6 μg / mL, Final [DOX] = 1 μg / mL.
[0016] Figure 6 Another set of TEM images of lyophilized reconstituted DOX / DNA is shown. High power (left) and ultra high power (right) images of DOX / DNA are shown. Final [DNA] = 6 μg / mL, Final [DOX] = 1 μg / mL.
[0017] Figure 7 Shown are two TEM images of DNA prepared in PBS and diluted in H 2 O. Final [DNA] = 6 μg / mL.
[0018] Figure 8 Two additional TEM images are shown at lower magnification of DNA prepared in PBS and diluted in H 2 O. Final [DNA] = 6 μg / mL.
[0019] Fig. 9 Shown is a gel photograph of a DNA degradation experiment performed in 10% FBS / PBS. DNA was incubated with serum-containing PBS at 37°C for a period of time. The samples were stored at -20°C to stop enzymatic degradation by nucleases at each time point. [DNA] = 100 μg / mL. The numbers on the left represent the base pairs in the ladder (L). 0*: Fresh DNA (no -20°C storage). DNA degrades over time when exposed to 10% FBS / PBS. Nucleases in serum-containing culture media may have contributed to this degradation. It can be inferred that the delayed release of DOX is caused by the degradation of DNA over time in 10% fetal bovine serum (FBS).
[0020] Fig.10 Results from a study looking at the in vitro cytotoxicity of DOX / DNA in EL4 cells at 24h, 48h, and 72h are presented. EL4 cells were treated three times with a range of concentrations for 24, 48, and 72h, and then cell viability was analyzed by MTT assay. At 24h in culture, DOX / DNA was less cytotoxic than DOX to these cells, with a difference of approximately 3.5-fold, as reported in the IC 50 Values shown: DOX / DNA IC 50 =1.143μg / mL or 2.1M, DOX IC 50 = μ0.313 g / mL or 0.576 M. At 48 and 72 h of culture, DOX / DNA was similarly cytotoxic to these cells as DOX, as reported in the IC 50 Values shown: DOX / DNA IC 50 =0.072μg / mL, DOX IC 50 = 0.093 μg / mL (at 48 hours), or DOX / DNA IC 50 =0.055 μg / mL, DOX IC 50 = 0.048 μg / mL (at 72 hours). This result together with the 24 hour cytotoxicity data indicates a delayed release of DOX from DOX / DNA. In addition, the results show that the nanoparticles exhibit less toxicity compared to the free small molecule counterparts.
[0021] Fig.11 Results of pharmacokinetic studies in EL4 tumor-bearing C57BL / 6 mice treated intravenously with 20 mg / kg DOX or DOX / DNA equivalent to 20 mg / kg DOX are shown. These mice were female mice aged 6-8 weeks. 1 / 2 Compared with mice treated with DOX / DNA (DOX / DNA:T = 3 minutes, n = 3), DOX / DNA had a longer blood circulation half-life in EL4 tumor-bearing C57BL / 6 mice (DOX / DNA:T 1 / 2 =75 minutes). DOX is absorbed by tissues within ~15 minutes (as indicated by the initial steep slope of the curve), and then a profile more like liver and kidney clearance is observed. However, the tissue uptake curve of DOX / DNA is far less steep and can last for 1 hour. It can be inferred from the above results that DOX recycling and DOX protection / shielding are enhanced due to the presence of DNA. Afterwards, features indicative of liver and kidney clearance are observed. Therefore, the drug delivery system of the present disclosure alters the dissolution and absorption of doxorubicin, potentially allowing for sustained release of the active agent.
[0022] Fig.12The binding kinetics of DOX to DNA are provided. The fluorescence of DOX / DNA was measured as [DOX] increased. [DNA] was kept constant at a concentration of 400 μg / mL, n=3.
[0023] Fig.13 It was shown that DOX bound to DNA decreased over 24 hours in FBS and PBS containing serum. [DNA] was constant at 400 g / mL. It is likely that DOX was released from DNA due to the presence of FBS.
[0024] Fig.14 The results showed that the serum content in the culture medium resulted in the release of DOX from DOX / DNA over time in a dose-dependent manner, with n = 3 replicates. The data obtained from the combined kinetics experiments showed that the rate of DOX release from DOX / DNA over time was dependent on the serum content in the culture medium. At least according to this model, the nanoparticles released most of the DOX within 72 hours.
[0025] Fig.15 Complete blood counts and liver enzyme panel analysis in C57BL / 6 mice treated with 20 mg / kg DOX, DOX / DNA equivalent to 20 mg / kg DOX, PBS, or 120 mg / kg DNA are presented, n=3.
[0026] Fig.16 Biodistribution of DOX and DOX / DNA at multiple time points after intravenous injection is provided. DOX accumulation in organs and tumor tissues 1, 3, 6, and 12 hours after intravenous administration of 20 mg / kg DOX, DOXIL (20 mg / kg DOX equivalent) or DOX / DNA (20 mg / kg DOX equivalent) to EL4 tumor-bearing C57BL / 6 mice (female, 6-8 weeks old). DOX accumulation in the lung was lower in the DOX / DNA group, n=5 (except DOXIL 12h, where n=3).
[0027] Fig.17 The biodistribution of DOX and DOX / DNA at multiple time points after intravenous injection in EL4 tumor-bearing C57BL / 6 mice is provided. DOX accumulation in organs and tumors 1, 3, 6 and 12 hours after intravenous injection of 20 mg / kg DOX, DOXIL (20 mg / kg DOX equivalent) or DOX / DNA (20 mg / kg DOX equivalent) to EL4 tumor-bearing C57BL / 6 mice (female, 6-8 weeks old). In the DOX / DNA group, DOX accumulation in the lung was low, n = 5 (except DOXIL 12h, where n = 3).
[0028] Fig.18The biodistribution of DOX and DOX / DNA at multiple time points after intravenous injection in EL4 tumor-bearing C57BL / 6 mice is provided. DOX accumulated in organs and tumors 1, 3, 6 and 12 hours after intravenous injection of 20 mg / kg DOX, DOXIL (20 mg / kg DOX equivalent) or DOX / DNA (20 mg / kg DOX equivalent) to EL4 tumor-bearing C57BL / 6 mice (female, 6-8 weeks old). In the DOX / DNA group, DOX accumulation in the lung was low, n = 5 (except DOXIL 12h, where n = 3).
[0029] Fig.19 Acute toxicity survival curves for C57BL / 6 mice (female, 6-8 weeks, n=7) are provided. No acute toxicity was observed at doses of 20 mg / kg or below. Acute toxicity (cardiac arrest) occurred in mice dosed with 40 mg / kg DOX.
[0030] Fig. 20 Tumor growth and survival of EL4 tumor-bearing mice (2-3 months old, female) were regularly tracked for 30 days after intravenous treatment with a range of doses of DOX / DNA, DOX or DOXIL. In EL4 tumor-bearing C57BL / 6 mice (n=5), DOX / DNA slowed tumor growth and improved survival. When using a nanocarrier formulation, the 20 mg / kg dose showed prolonged survival and slowed tumor growth. Interestingly, until day 28, the tumors of mice treated with 40 mg / kg DOX / DNA completely regressed. In addition, 60% of these mice survived until the end of the experiment. These results effectively demonstrate that DNA has the function of increasing the maximum tolerated dose of DOX, and also demonstrates its protective effect against systemic toxicity. This may mean improved survival and quality of life for human treatment subjects. The body weight of EL4 tumor-bearing mice (2-3 months old, female) was regularly tracked for 30 days after intravenous treatment with a range of doses of DOX / DNA, DOX or DOXIL. High-dose DOX / DNA treatment resulted in weight loss in EL4 tumor-bearing C57BL / 6 mice (n=5).
[0031] Fig.21 Results of body weight, tumor growth, and survival of EL4 tumor-bearing C57BL / 6 mice (6 weeks) treated with 20 mg / kg DOX or DOX equivalents of DOXIL or DOX / DNA on days 0, 7, and 14 are presented, n=5. DOX / DNA treatment resulted in more favorable results compared to free DOX or DOXIL. DOX / DNA is safer than free DOX. In addition, DOX / DNA treatment had the most significant reduction in tumor growth and the highest survival rate.
[0032] Fig. 22 Shows that DOX / DNA uptake in EL4 cells is inhibited by endocytosis inhibitors. Positive control: No inhibitor. Clathrin-dependent pathway: Chlorpromazine (CPZ) 20μM. Caveolin-dependent pathway: Filipin III 5μg / mL. Macropinocytosis pathway: EIPA 20μM. These concentrations were chosen based on dose-response analysis of each inhibitor. Based on the above, cells take up NPs via both clathrin-dependent and caveolin-dependent pathways. Membrane fusion is also involved, as shown by the 4°C inhibition of DOX / DNA uptake.
[0033] Fig.23 Shown is the EL4 DOX uptake after exposure to the inhibitors NaN3, PS2, Filipin III, EIPA or 4° C. Inhibition studies indicate that DOX is taken up by cells primarily via membrane fusion.
[0034] Fig.24 Provided are confocal laser scanning microscopy (CLSM) images of EL4 cells treated with DOX / DNA-Cy5 from 0 to 8 hours. The images show uptake of DOX / DNA by EL4 cells over time. These images further demonstrate internalization of the nanoparticles, not just DOX alone.
[0035] Fig.25 Titration curves of DOX, DNA, and DOX / DNA using weak bases are shown. The pH of each solution was lowered to below 2 with 1M HCl. The pH was measured after each addition of 100 μL or 20 μL of 0.1M NaOH. DNA pKa ranged from 1 (phosphate), 6-7 (phosphate). DOX pKa was 7.34 (phenol), 8.46 (amine), 9.46 (estimated). DETAILED DESCRIPTION OF THE INVENTION
[0037] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a vector" includes a plurality of such vectors and reference to "a nucleic acid" includes reference to one or more nucleic acids and equivalents thereof known to those skilled in the art, and so forth.
[0038] Additionally, the use of "or" means "and / or" unless stated otherwise. Similarly, "include" and "comprising" are interchangeable and not limiting.
[0039] It should also be understood that where the term “comprising” is used in the description of various embodiments, those skilled in the art will understand that in some specific cases, the language “consisting mainly of” or “consisting of” may alternatively be used to describe the embodiments.
[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although many methods and reagents are similar or equivalent to those described herein, exemplary methods and materials are disclosed.
[0041] All publications mentioned herein are incorporated herein by reference in their entirety to describe and disclose methods that may be relevant to the present description. In addition, with respect to any terms that appear in one or more publications that are similar or identical to terms that have been expressly defined in this disclosure, the definitions of the terms expressly provided in this disclosure will control in all respects.
[0042] For the purposes of this disclosure, the term "cancer" will be used to include cell proliferative disorders, tumors, precancerous cell disorders, and cancers, unless specifically described otherwise. Thus, "cancer" refers to any cell that undergoes abnormal cell proliferation, which can lead to metastasis or tumor growth. Exemplary cancers include, but are not limited to, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphomas, anal cancer, anorectal cancer, anal canal cancer, appendix cancer, childhood cerebellar astrocytoma, childhood brain astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), bile duct cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumors, brain stem gliomas, cerebellar astrocytoma, brain astrocytoma / glioblastoma, ependymoma, medulloblastoma visual pathway and hypothalamic glioma, breast cancer including triple negative breast cancer, bronchial adenoma / carcinoid, carcinoid tumor, gastrointestinal, nervous system cancer, Nervous system lymphoma, Central nervous system cancer, Central nervous system lymphoma, Cervical cancer, Childhood cancer, Chronic lymphocytic leukemia, Chronic myeloid leukemia, Chronic myeloproliferative disease, Colon cancer, Colorectal cancer, Cutaneous T-cell lymphoma, Lymphoma, Mycosis fungoides, Seizure Ali syndrome, Endometrial cancer, Esophageal cancer, Extracranial germ cell tumor, Extragonadal germ cell tumor, Extrahepatic bile duct cancer, Eye cancer, Intraocular melanoma, Retinoblastoma, Gallbladder cancer, Gastric cancer, Gastrointestinal carcinoid tumor, Gastrointestinal stromal tumor (GIST), Germ cell tumor, Ovarian germ cell tumor, Gestational trophoblastic tumor, Glioma, Head and neck cancer, Hepatocellular (liver) cancer, Hodgkin lymphoma, Hypopharyngeal cancer , intraocular melanoma, eye cancer, islet cell tumor (endocrine pancreas), Kaposi's sarcoma, kidney cancer, renal cancer, laryngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, lip and oral cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, AIDS-related lymphoma, non-Hodgkin's lymphoma, primary central nervous system lymphoma, Waldenstrom's macroglobulinemia, medulloblastoma, melanoma, intraocular (eye) melanoma, Merkel cell carcinoma, mesothelioma malignant, mesothelioma, metastatic squamous neck cancer, oral cancer, tongue cancer, multiple endocrine neoplasia syndrome, mycosis fungoides, myelodysplastic syndrome Syndrome, myelodysplastic / myeloproliferative diseases, chronic myeloid leukemia, acute myeloid leukemia, multiple myeloma, chronic myeloproliferative diseases, nasopharyngeal carcinoma, neuroblastoma, oral cancer, oral cancer, oropharyngeal cancer, ovarian cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal cell tumor and supratentorial primitive neuroectodermal tumor, pituitary tumor, plasma cell tumor / multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal pelvis and ureter, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Ewing's sarcoma family of tumors, soft tissue sarcoma, uterine cancer, uterine sarcoma, skin cancer (non-melanoma),Skin cancer (melanoma), papilloma, actinic keratoses and keratoacanthomas, Merkel cell tumors, gastric cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, laryngeal cancer, thymoma, thymoma and thymiccarcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter and other urinary organs, gestational trophoblastic tumor, urethral cancer, endometrial cancer, uterine sarcoma, uterine corpus cancer, vaginal cancer, vulvar cancer and Wilms tumor. In a specific embodiment, the cancer is selected from acute lymphoblastic leukemia, acute myeloid leukemia, osteosarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, kidney cancer, multiple myeloma, neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thymoma, thyroid cancer, transitional cell bladder cancer, uterine sarcoma, Wilms' tumor and Waldenstrom's macroglobulinemia.
[0043] As used herein, the term "disorder" is generally synonymous and may be used interchangeably with the terms "disease," "complication," and "condition" (as in medical condition) because they all reflect an abnormal condition of the human or animal body or one of its parts in which normal function is impaired, usually manifested by obvious signs and symptoms.
[0044] As used herein, the term "non-release controlling excipient" refers to an excipient whose primary function does not include changing the duration or location of release of the active substance from the dosage form compared to conventional immediate release dosage forms.
[0045] The terms "pharmaceutically acceptable carrier", "pharmaceutically acceptable excipient", "physiologically acceptable carrier" or "physiologically acceptable excipient" as used herein refer to pharmaceutically acceptable materials, compositions or carriers, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials. Each component should be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical formulation. It should also be suitable for use in contact with human and animal tissues or organs, without excessive toxicity, irritation, allergic reaction, immunogenicity or other problems or complications, and in accordance with a reasonable benefit / risk ratio. Examples of "pharmaceutically acceptable carriers" and "pharmaceutically acceptable excipients" are found in Remington: The Science and Practice of Pharmacy, 21st Edition; Lippincott Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 5th Edition; Rowet al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and Handbook of Pharmaceutical Additives, 3rd Edition; Ash and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, Gibson Ed., CRC Press LLC: Boca Raton, Fla., 2004.
[0046] As used herein, the term "therapeutic agent that can associate or bind to DNA or RNA" refers to a small molecule that can associate or bind to DNA or RNA and can be used to treat a disorder or disease (usually cancer) in a subject. Examples of "therapeutic agents that can associate or bind to DNA or RNA" include, but are not limited to, anthracyclines such as aclarubicin, amrubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, valrubicin, and daurubicin; anthracenediones such as mitoxantrone and pyranone; camptothecins such as belotecan, camptothecin, cocinotecan, esnotecan, gimenotecan, irinotecan, rutotecan, rubitecan, silatecan, and topotecan; podophyllotoxins such as etoposide and teniposide; bleomycin; actinomycin D; minor groove binders such as duocarmycin A, adozerecine, biserecine, and kazerecine; purine antagonists such as cladribine, clofarabine, nelarabine, mercuroguanine, thioguanine, and pentotecan. d-Butyl; pyrimidine antagonists such as capecitabine, carmofor, doxeridine, floxuridine, fluorouracil, tegafur, cytarabine, gemcitabine, azacytidine and decitabine; folic acid antagonists such as aminopterin, methotrexate, pemetrexed and pratraxac; alkylating agents such as cyclophosphamide, ifosfamide, trofosmine, chlorambucil, melphalan, pradidin, bendamustine, chlormethine, urapidil, carmustine, fotemustine, lomustine, nimustine, lanimustine, streptozotocin, manosan, troxostatin, carboplatin, thiotepa, triazinecycline, triethylendaplatin, carboplatin, cisplatin, dicycloplatin, nedaplatin, oxaliplatin, satarapradin, temozolomide, dacarbazine, mitrobronisol, pipoman and procaine.
[0047] The term "controlled release excipient" as used herein refers to an excipient whose main function is to change the duration or location of release of an active substance from a dosage form compared to a conventional immediate release dosage form.
[0048] The term "therapeutically acceptable" refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) that are suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, immunogenicity, consistent with a reasonable benefit / risk ratio, and effective for their intended use.
[0049] As used herein, the term "treat" refers to ameliorating symptoms associated with a disease or disorder (eg, cancer), including preventing or delaying the onset of disease or disorder symptoms, and / or reducing the severity or frequency of disease or disorder symptoms.
[0050] The term "subject" used in the present invention refers to animals, including but not limited to primates (e.g., humans, monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, etc.), lagomorphs, pigs (e.g., pigs, miniature pigs), horses, dogs, cats, etc. The terms "subject" and "patient" are used interchangeably in the present invention. For example, a mammalian subject may refer to a human patient.
[0051] Therapeutic agents that can be associated or combined with DNA or RNA have great potential in treating cancer and other diseases, but their inherent chemical structure makes them insoluble, resulting in low bioavailability. Although some of these therapeutic agents are soluble, they can cause systemic toxicity and are usually cleared from the body too quickly. Current solutions to these problems include the use of nanocarriers to deliver such compounds (e.g., anthracycline antibiotics). However, the common disadvantages of these solutions include very low drug loading, immunogenicity, poor therapeutic effect, slow carrier clearance, and a significant increase in cost. For example, the PEGylated (pegylated) liposomal formulation of doxorubicin (DOX), DOXIL, has experienced all these limitations. Although it improves the safety of doxorubicin, its efficacy is not as good as DOX. The long circulation of DOXIL in the bloodstream actually allows the immune system to produce antibodies against the PEGylated portion on the particles. Therefore, the main disadvantages of the current solution include the biocompatibility of the nanocarrier. In addition, the current solution is not easy to assemble. In direct contrast, the compositions and methods disclosed herein can be assembled in a direct manner and are more cost-effective. For example, another DOX nanocarrier, HPMA-DOX (N-(2-hydroxypropyl) methacrylamide polymer-doxorubicin), is reported to have a shorter circulation time (20.1 hours) than the composition described in the present invention and a more complex assembly process, which will be difficult to scale up to commercial levels. Others have synthesized nucleic acid systems for delivering chemotherapy (e.g., click nucleic acids for DOX and cytosine deaminase delivery), but such preparations are quite time-consuming and expensive and are unlikely to reach the commercial stage. In addition, PEGylation of such preparations may lead to similar immunogenicity issues, which have been reported in other PEGylated drug delivery systems (such as DOXIL).
[0052] As shown in the in vitro and in vivo studies described in the present invention, the use of nucleic acid fragments as delivery vehicles for DOX improves the safety and efficacy of induced solid tumor treatment in mice. In particular, in the in vivo studies introduced in the present invention, DOX / DNA nanoparticle treatment improved survival and slowed tumor growth compared to DOX treatment alone. The above favorable results may be the result of prolonged DOX / DNA nanoparticle circulation time and controlled release of DOX from DNA, as demonstrated by 24-hour, 48-hour and 72-hour in vitro cytotoxicity studies and in vivo blood circulation studies. Both methods allow DOX / DNA nanoparticles to exert a chemotherapeutic effect that is superior to DOX treatment alone and to DOXIL treatment. This study shows that DOXIL can effectively reduce systemic toxic effects, but does not improve treatment outcomes. In addition, studies have shown that PEGylation of DOXIL and repeated administration of the chemotherapeutic formulation can lead to immunogenicity. Unfortunately, other delivery vehicles in the field of nanotherapy can be very complex in terms of their formulation and production, making them difficult to expand. Therapeutic agents and nucleic acids have been produced on a commercial scale. Therefore, therapeutic agent / nucleic acid formulations, preparations and compositions are easy to produce and can be commercially expanded.
[0053] In certain embodiments, the present disclosure provides a composition, formulation or formulation comprising one or more therapeutic agents that have been complexed with nucleic acids to form nanoparticles. Examples of therapeutic agents that can be complexed with nucleic acids to form nanoparticles include, but are not limited to, norepinephrine reuptake inhibitors (NRIs), such as atomoxetine; dopamine reuptake inhibitors (DARIs), such as methylphenidate; serotonin-norepinephrine reuptake inhibitors (SNRIs), such as milnacipran; sedatives, such as diazepam; norepinephrine-dopamine reuptake inhibitors, such as bupropion; serotonin-norepinephrine-dopamine-reuptake inhibitors, such as venlafaxine; monoamine oxidase inhibitors, such as selegiline; hypothalamic phospholipids; endothelin-converting enzyme (ECE) inhibitors, such as phosphamide; thromboxane receptor antagonists, such as etanercept; potassium channel openers; thrombin inhibitors, such as hirudin; hypothalamic phospholipids; growth factor inhibitors, such as PDGF activity modulators; platelet activating factor (PAF) antagonists; low molecular weight heparins, such as enoxaparin; factor VIIa inhibitors and factor Xa inhibitors; renin inhibitors; neutral endopeptidase (NEP) inhibitors; vascular pepsin inhibitors (dual NEP-ACE inhibitors), such as omapatrilat and gemotrilat; HMG-CoA reductase inhibitors, such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (also known as itavastatin, nivolumab, and sirolimus); statins or nicotinic acid) and ZD-4522 (also known as rosuvastatin, atorvastatin or visastatin); squalene synthetase inhibitors; fibrates; bile acid sequestrants, such as cholestyramine; niacin; antiatherosclerotic agents, such as ACAT inhibitors; MTP inhibitors; calcium channel blockers, such as amlodipine besylate; potassium channel activators; alpha-muscarinics; beta-muscarinics, such as carvedilol and metoprolol; antiarrhythmics; diuretics, such as chlorothiazide, hydrochlorothiazide, fluazifop, hydrofluoromethyl azide, benzylfluoromethyl azide, methylchlorothiazide, trichloromethyl azide, polythiazide, benzothiazide, ethafazinic acid, phenoxyethylamine, chlorpromazine ... tricrynafen, chlorthalidone, furanilamide, musolimine, bumetanide, triazone, amiloride, and spironolactone; antidiabetic agents, such as biguanides (e.g., metformin), glucosidase inhibitors (e.g., acarbose), insulin, meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, and glipizide), thiazolidinediones (e.g., troglitazone, rosiglitazone, and pioglitazone), and PPAR-γ agonists; mineralocorticoid receptor antagonists, such as spironolactone and eplerenone; growth hormone secretagogues; aP2 inhibitors; phosphodiesterase inhibitors, such as PDE III inhibitors (such as cilostazol) and PDE V inhibitors (such as sildenafil, tadalafil, vardenafil); protein tyrosine kinase inhibitors; antiproliferative drugs, such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate mofetil; chemotherapeutic drugs; immunosuppressants;Anticancer and cytotoxic agents (e.g., alkylating agents such as nitrogen mustards, alkyl sulfonates, nitrosoureas, ethyleneimines, and triazenes); antimetabolites such as folate antagonists, purine analogs, and pyridine analogs; antibiotics such as anthracyclines, bleomycin, actinomycin, dacarbamycin, and phyllomycin; enzymes such as L-asparaginase; farnesyl-protein transferase inhibitors; hormones such as glucocorticoids (e.g., cortisone), estrogens / antiestrogens, androgens / antiandrogens, progestins, and luteinizing hormone-releasing hormone antagonists, and octreotide acetate; microtubule disruptors such as scutellaria toxin; microtubule stabilizers such as paclitaxel, docetaxel, and epothilone A F; products of plant origin, such as vinca alkaloids, epipodophyllotoxins and taxanes; and topoisomerase inhibitors; polyphenolic compounds; polyketides; isoprene-protein transferase inhibitors; and cyclosporins; cytotoxic drugs, such as azathioprine and cyclophosphamide; TNF-α inhibitors, such as tenidap; anti-TNF antibodies or soluble TNF receptors, such as etanercept, rapamycin and leflunomide; and cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; and various agents, such as hydroxyurea, procarbazine, mitotane, hexamethylmelamine, gold compounds, platinum coordination complexes, such as cisplatin, satradin and carboplatin. Although the exemplary studies presented in the present invention clearly show that the DOX / nucleic acid nanoparticles disclosed in the present invention can be used to effectively treat cancer, it should be understood that any disease or condition that can be treated by a therapeutic agent is covered in the present disclosure. ;
[0054] In a specific embodiment, the present disclosure provides a therapeutic composition, formulation or formula comprising a polyphenol that has been complexed with a nucleic acid to form a nanoparticle. Polyphenols are a class of structures composed primarily of natural, but also synthetic or semi-synthetic organic chemicals, characterized by the presence of a large number of phenolic structural units. The number and characteristics of these phenolic structures are the basis for the unique physical, chemical and biological (metabolic, toxic, therapeutic, etc.) properties of specific members of this class. Many polyphenols are micronutrients produced by dietary plants as secondary metabolites. Although these compounds exhibit poor bioavailability (only a portion of the ingested amount is absorbed and they are excreted rapidly), as well as complex pharmacodynamics and metabolism, they still have therapeutic properties. A large body of evidence (epidemiological studies, animal studies and human clinical trials) shows that polyphenols can reduce a range of pathologies associated with cardiovascular disease, including thrombosis ( J Agric Food Chem. 2008; 56: 2970–2976.), atherosclerosis (Chiva-Blanch et al., Am J Clin Nutr. 2012; 95: 326–334.) and inflammation (Rieder et al., Br J Pharmacol. 2012; 167: 1244–1258.), as well as showing anticancer (Gali et al., Cancer Res. 1991; 51: 2820–2825.) and neuroprotective (Gatson et al., J Trauma Acute Care Surg. 2013; 74: 470–475) properties. The activity of these compounds is achieved through a range of mechanisms, including their significant antioxidant effects (Pignatelli et al., Atherosclerosis. 2006; 188: 77–83), inhibition of intracellular kinase activity (Wright et al., Regen Med. 2012; 7: 295–307), binding to cell surface receptors (Jacobson et al., Adv Exp Med Biol. 2002; 505: 163–171), and disruption of cell membrane integrity (Pawlikowska-Pawlega et al., Biochim Biophys Acta. 2007; 1768: 2195–2204). The application of polyphenols has increased, especially in the functional food, nutraceutical and pharmaceutical industries. However, the effectiveness of polyphenols is a concern for human health, which depends on maintaining the stability, bioactivity and bioavailability of the bioactive compounds. In addition, the unpleasant taste of some phenolic compounds limits their use in pharmaceutical applications. The encapsulation or complexation of polyphenols disclosed in the present invention with nucleic acids can help to address these shortcomings of free polyphenolic compounds. Since the compositions and methods disclosed in the present invention are controlled by a platform-based polyphenol delivery system, it is expected that any type of polyphenol can be complexed or encapsulated by the nucleic acids disclosed in the present invention. Examples of such polyphenolic compounds include, but are not limited to, xanthohumol; flavanols such as epicatechin, epigallocatechin, epigallocatechin gallate, and proanthocyanidins; flavanones such as hesperidin and naringenin; flavonoids such as apigenin, chrysin, and luteolin; flavonols such as quercetin, kaempferol, myricetin, isorhamnetin, and galangin; isoflavones such as genistein and daidzein; phenolic acids such as ellagic acid, gallic acid, ferulic acid, chlorogenic acid; lignans such as sesamone and flax lignan diglucoside; stilbenes such as resveratrol, pterostilbene, and piceatannol. Thus, the present disclosure provides a platform technology for the safe, effective and controlled delivery of polyphenolic formulations, compositions or preparations to treat any disease or condition treatable with polyphenolic compounds.For example, a large number of studies have shown that polyphenols can limit the incidence of coronary heart disease (Renaud et al., Lancet. 1992; 339:1523–1526; Dubick et al., J Nutraceut Functional & Med Foods. 2001; 3:67–93; Nardini et al., Platelets. 2007; 18:224–243; and Vita et al., Am J Clin Nutr. 2005; 81:292–297); type II diabetes (Rizvi et al., Clin Exp Pharmacol Physiol. 2005; 32:70–75; Matsui et al., J Agric Food Chem. 2002; 50:7244–7248; Dembinska-Kiec et al., Br J Nutr 20. 2008; 99:109–117; and Chen et al., Am J Clin Nutr. 2005; 81:292–297); al., Eur J Pharmacol. 2007; 568: 269-277); obstructive pulmonary disease (Tabak et al., Am J Respir Crit Care Med. 2001; 164: 61-64; and Woods et al., Am J Clin Nutr. 2003; 78: 414-421); and neurodegenerative diseases (Ajami et al., Neuroscience & Biobehavioral Reviews 2007; 73: 39-47; and Mandel et al., Free Radical Biology and Medicine 2004; 37 (3): 304-317). It should be further noted that the formulations, compositions or preparations disclosed herein are not limited to the delivery of a specific polyphenolic compound, as any number of polyphenolic compounds can be complexed with the nucleic acids disclosed herein to prepare polyphenol / nucleic acid nanoparticles.
[0055] In addition, polyketides can be complexed with the nucleic acids disclosed in the present invention, or both polyketides and polyphenolic compounds can be complexed with the nucleic acids disclosed in the present invention. Polyketides are a large class of secondary metabolites that contain alternating carbonyl and methylene groups (-CO-CH2-), or are derived from precursors containing such alternating groups. Many polyketides have antimicrobial and immunosuppressive properties. Like polyphenolic compounds, polyketides can form pi-pi stacking interactions with the nucleic acid species disclosed in the present invention to form polyketide / nucleic acid nanoparticles.
[0056] In a specific embodiment, the present disclosure provides a composition, formulation or formulation comprising one or more therapeutic agents that can associate or bind to the disclosed DNA or RNA, which composition, formulation or formulation is complexed with the nucleic acid to form a nanoparticle. Examples of therapeutic agents that can be complexed with nucleic acids to form nanoparticles include, but are not limited to, anthracyclines such as aclarubicin, amrubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, valrubicin, and doxyrubicin; anthracenediones such as mitoxantrone and pyranone; camptothecins such as belotecan, camptothecin, cocinotecan, esnotecan, gimenotecan, irinotecan, rutotecan, rubitecan, silatecan, and topotecan; podophyllotoxins such as etoposide and teniposide; bleomycin; actinomycin D; minor groove binders such as duocarmycin A, adozerecine, biserecine, and kadreecine; purine antagonists such as cladribine, clofarabine, nelarabine, mercuroguanine, thioguanine, and pentotecan. d-butyl; pyrimidine antagonists, such as capecitabine, carmofor, doxeridine, floxuridine, fluorouracil, tegafur, cytarabine, gemcitabine, azacytidine and decitabine; folic acid antagonists, such as aminopterin, methotrexate, pemetrexed and pratraxac; alkylating agents, such as cyclophosphamide, ifosfamide, trofosmine, chlorambucil, melphalan, pradidin, bendamustine, chlormethine, uracil mustard, carmustine, fotemustine, lomustine, nimustine, laromustine, streptozotocin, mannosamine, trosulfuron, carboplatin, thiotepa, triazone, triethylmelamine, carboplatin, cisplatin, dicycloplatin, nedaplatin, oxaliplatin, satarapradin, temozolomide, dacarbazine, mitrobronisol, pipolome and procarbazine. In certain embodiments, the one or more therapeutic agents that can associate or bind to DNA or RNA are selected from anthracyclines such as aclarubicin, amrubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, valrubicin, and doxyrubicin; anthracenediones such as mitoxantrone and pyranone; camptothecins such as belotecan, camptothecin, cocinotecan, esnotecan, gimenotecan, irinotecan, rutotecan, rubitecan, silatecan, and topotecan; podophyllotoxins such as etoposide and teniposide; bleomycin; actinomycin D; and minor groove binders such as duocarmycin A, adozerecine, bicerecine, and kazerecine. In another embodiment, one or more therapeutic agents that can be associated or bound to DNA or RNA include aclarubicin, amrubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, valrubicin and / or daurubicin. In another embodiment, one or more therapeutic agents that can be associated or bound to DNA or RNA include mitoxantrone, topotecan, etoposide, teniposide, bleomycin, actinomycin D and / or duocarmycin A.
[0057] Since the compositions and methods disclosed in the present invention are controlled by a platform-based therapeutic delivery system, it is expected that any type of therapeutic compound that associates or binds to DNA or RNA can be complexed or encapsulated by the nucleic acids disclosed in the present invention. Illustrative examples of such therapeutic compounds include, but are not limited to, anthracyclines such as aclarubicin, amrubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, valrubicin, and daurubicin; anthracenediones such as mitoxantrone and pyranone; camptothecins such as belotecan, camptothecin, cosinotecan, esnotecan, gimenotecan, irinotecan, rutotecan, rubitecan, silatecan, and topotecan; podophyllotoxin compounds such as etoposide and teniposide; bleomycin; and actinomycin D; Therefore, the present disclosure provides a platform technology that can be used to safely, effectively, and controllably deliver formulations, compositions, or formulations of therapeutic agents that can associate or bind to DNA or RNA to treat any number of diseases or conditions that can be treated by the therapeutic agent. Although the exemplary studies presented herein clearly demonstrate that the DOX / nucleic acid nanoparticles disclosed herein can be used to effectively treat cancer, it should be understood that any disease or condition that can be treated by a therapeutic agent that can associate or bind to DNA or RNA is encompassed by the present disclosure. It should be further noted that the formulations, compositions, or formulations disclosed herein are not limited to delivering only one specific therapeutic agent that can associate or bind to DNA or RNA, because any number of therapeutic agents that can associate or bind to DNA or RNA can be complexed with the nucleic acids disclosed herein to prepare therapeutic agent / nucleic acid nanoparticles.
[0058] Regarding the nucleic acid component of therapeutic / nucleic acid nanoparticles, nucleic acid materials of any type and length can be used to complex with therapeutic agents that can associate or bind to DNA or RNA. That is, this type of nucleic acid should be able to form a pi-pi stacking interaction with a therapeutic agent that associates or binds to DNA or RNA. Although DNA is used in the studies described in the present invention, it is envisioned that DNA, RNA, DNA-RNA hybrids, or mixtures thereof can be used to form therapeutic agents / nucleic acid nanoparticles described in the present invention. In addition, for the purposes of this disclosure, "nucleic acid" includes nucleic acid analogs. Nucleic acids are nucleotide chains composed of three parts: a phosphate backbone, a pentose (ribose or deoxyribose), and one of the four bases. A nucleic acid analog may have any of these changes.
[0059] DNA (short for deoxyribonucleic acid) is an organic chemical with a complex molecular structure that is present in all prokaryotic and eukaryotic cells and in many viruses. DNA encodes genetic information for the transmission of hereditary traits. Each strand of a DNA molecule consists of a long chain of monomeric nucleotides. A DNA nucleotide consists of a deoxyribose sugar molecule attached to a phosphate group and one of four nitrogenous bases, two purines (adenine and guanine) and two pyrimidines (cytosine and thymine). The nucleotides are linked together by covalent bonds between the phosphate of one nucleotide and the sugar of the next, thereby forming a phosphate-sugar backbone from which the nitrogenous bases protrude. One strand joins the other strand by hydrogen bonds between the bases, and the order of this bonding is specific, i.e. adenine only bonds to thymine and cytosine only to guanine. The DNA molecule is in a very stable configuration and can serve as a template for the replication of new DNA molecules and the production (transcription) of related RNA (ribonucleic acid) molecules.
[0060] RNA, short for ribonucleic acid, is a high molecular weight complex that plays a role in cellular protein synthesis and replaces DNA (deoxyribonucleic acid) as a carrier of the genetic code in some viruses. RNA consists of ribonucleotides (nitrogenous bases attached to the ribose sugar) linked by phosphodiester bonds to form chains of varying lengths. The nitrogenous bases in RNA are adenine, guanine, cytosine, and uracil (which replace thymine in DNA). The ribose of RNA is a ring structure consisting of five carbons and one oxygen. A chemically reactive hydroxyl (-OH) group is attached to the second carbon atom in the ribose molecule, which makes RNA susceptible to hydrolysis. This chemical instability of RNA is believed to be one of the reasons why DNA has evolved to become the preferred carrier of genetic information in most organisms, compared to DNA, which does not have a reactive -OH group at the same position of the sugar part (deoxyribose). In a specific embodiment, the reactive -OH group of RNA can be replaced by a less reactive -O-alkyl group or halide group to make the RNA resistant to the action of RNases.
[0061] DNA-RNA hybrids are abundant in human cells. They are formed during transcription when a nascent RNA is in close proximity to its DNA template. The resulting RNA / DNA hybrid and displaced single-stranded (ss)DNA are called R-loops. RNA / DNA hybrids are structurally different and more stable than the corresponding double-stranded DNA. RNA / DNA hybrids are found in replication origins, immunoglobulin class switch regions, and transcription complexes. RNA / DNA hybrids do not adopt the traditional DNA B-conformation or RNA A-conformation, but exist as hybrids or heteroduplexes.
[0062] For the purposes disclosed herein, nucleic acid fragments can be produced by enzyme digestion or physical cleavage of naturally occurring nucleic acids, chemically synthesized nucleic acids of various sizes, or some combination thereof. Any naturally occurring nucleic acid can be used, including nucleic acids from any species, from prokaryotes, from eukaryotes, from fungi, etc. In a specific embodiment, the nucleic acid fragments are from salmon DNA. In addition, the size / length of the nucleic acid fragments can be changed to suit the specific therapeutic agent used. For example, the length of the nucleic acid fragment can be 20nt, 30nt, 40nt, 50nt, 60nt, 70nt, 80nt, 90nt, 100nt, 110nt, 120nt, 130nt, 140nt, 150nt, 160nt, 170nt, 180nt, 190nt, 200nt, 250nt, 300nt, 350nt, 400nt, 450nt, 500nt, 550nt, 600nt, 650nt, 700nt, 750nt, 800nt, 850nt, 900nt, 950nt. In some embodiments, the nucleic acid nanoparticles can be selected from nucleic acid nanoparticles of the present invention. The nucleic acid nanoparticles of the present invention ... Ligands for tumor-specific antigens are commercially available from a variety of suppliers and therefore do not have to be generated de novo (e.g., see Elabscience, Santa Cruz biotechnology, Biospacific, Novus Biologicals, etc.). In a specific embodiment, the ligand attached to the therapeutic agent / nucleic acid nanoparticle is selected from alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, CA15-3, CA19-9, MUC-1, epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), abnormal products of ras or p53, CTAG1B, MAGE1 and HER2 / neu tumor-specific antigen binding. The ligand that binds to the tumor-specific antigen should have a high affinity for binding to the target antigen (Kd<10nM) to be effectively taken up into the target tumor cells, and the immunogenicity should be minimal. In another embodiment, the ligand that binds to the tumor-specific antigen is connected to the therapeutic agent / nucleic acid nanoparticle disclosed in the present invention by using a cleavable linker (acid-labile linker, protease-cleavable linker, and disulfide bond linker). The acid-labile linker is designed to be stable at the pH level encountered in the blood, but becomes unstable and degraded when encountering a low pH environment in the lysosome. The protease-cleavable linker is also designed to be stable in blood / plasma, but will be in the lysosome of the cancer cell, after being cleaved by the lysosomal enzyme, the free drug is quickly released. They utilize the high level of protease activity within the lysosome and include peptide sequences that are recognized and cleaved by these proteases, just like the connection of the Val-Cit dipeptide that is rapidly hydrolyzed by cathepsin. The third type of linker that can be used to connect the ligand to the therapeutic agent / nucleic acid nanoparticle contains a disulfide bond. This linker utilizes the high level of reduced glutathione in cells to release free drugs inside cells. Reagents such as Traut's reagent (2-iminothiolane), MBS (3-maleimidobenzoic acid N-hydroxysuccinimide ester), and SATA (N-succinimidyl S-acetylthioacetate) can convert these primary amine groups into sulfhydryls, which can then form disulfide bonds with ligands containing cysteine residues. Other reagents such as SPDP (N-succinimidyl 3-(2-pyridyldithio) propionate), SMCC (succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate), and sulfo-SMCC can be used as linkers to attach ligands to nucleic acids of therapeutic agent / nucleic acid nanoparticles. Examples of how to use these groups to attach ligands to therapeutic agents / nucleic acid nanoparticles can be found on the global website (labome.com / method / Antibody-Conjugation.html) and in the references cited herein, including Safdari et al., Monoclon Antib Immunodiagn Immunother. 2013 32:409-12; Joosten V et al., Microb Cell Fact. 2003 2:1; Winter et al., Trends Pharmacol Sci. 1993 14:139-43; Arbabi et al., Front Immunol. 2017 8:1589; Brinkley et al., Bioconjug Chem. 1992 3:2-13; Vlasak et al., MAbs. 2011 3:253-63; Ducancel et al., MAbs. 20124:445-57;McCombs et al.,AAPS J.2015;17:339-51;Hondal R.,Protein Pept Lett.2005 12:757-64;Zimmerman et al.,BioconjugChem.2014 251-361-Traut et al. al.,Biochemistry.1973 12:3266-73;Knight P.,Biochem J.1979 179:191-7;Carlsson et al.,Biochem J.1978 173:723-37;Peeters Jet al.,J Immunol Methods.1998. 120:133-43;Hashida et al.,J Appl Biochem.19846:56-63;Avrameas et al.,Immunochemistry.1971 8:1175-9;Richards et al.,JMolBiol.1968 37:23-31Chandler, Immundler et al. Methods.1982 53:187-94;Coulepiset al.,J Clin Microbiol.1985 22:119-24;White et al.,J Clin Microbiol.1989 27:2300-4;Liu et al.,JImmunol Methods.2000. 234:P153-67;Tian et al.,BioconjugChem.2015 26:1144-55;Vira etal.,Anal Biochem.2010 402:146-50;Szabóet al.,Biophys J.2018 81-4068:Hagan et al. al.,Lanthanide-Anal Bioanal Chem.2011400:2847-64;Han et al.Nat Protoc.2018 13:2121-2148;Bottrill et al.,Chem SocRev.2006 35:557-71;Yelin et al., Lab.Jal.2014. 28:335-40;Fernández Moreiraet al.,Analyst.2010 135:42-52;Brouwers et al.,J Nucl Med.200445:327-37; Vera et al., Nucl Med Biol. 2012 39: 3-13; Stein et al., J Nucl Med. 2001 42: 967-74; Bratthauer G., Methods Mol Biol. 2010 588: 257-70; Engle et al., Science. 2019 2014 1199:67-83; Tan et al. al., Nanomaterials (Basel). 20155: 1297-1316; Geng et al., Bioconjug Chem. 2016 27: 2287-2300; Pecanha et al., J Immunol. 1991 146: 833-9; Pecanha et al., J Immunol. 1993 150: 2160-8; and Chen Y., Methods Mol Biol. 2013 1045: 267-73, the disclosures of which are incorporated herein by reference.
[0063] Although the exemplary DOX / DNA nanoparticles disclosed in the research described in the present invention are polydisperse due to the properties of the natural nucleic acids used, it is expected that monodisperse nanoparticles can be prepared based on the selection of nucleic acids. Such monodisperse nanoparticles can impart better therapeutic effects. In addition, the nucleic acids constituting the nanoparticles disclosed in the present invention can be compounded with cationic molecules (e.g., PTD domains) to provide or improve the controlled release properties of the nanoparticles (by minimizing degradation caused by nucleases). In addition, the hygroscopic properties of nucleic acids can be used to prepare hydrogels loaded with therapeutic agents, and the nucleic acids can be conjugated with proteins (e.g., thymosin-α1) to provide a multimodal method for treating diseases or disorders with the nanoparticles disclosed in the present invention. For example, therapeutic / nucleic acid nanoparticles can be conjugated with immune enhancing proteins such as thymosin-α1 to deliver a multimodal method of anti-cancer therapeutic compounds while eliciting the immune system to fight cancer.
[0064] The therapeutic agent can be compounded with nucleic acid at a certain weight ratio (wt / wt) to form nanoparticles. For example, the weight / weight ratio of nucleic acid fragments and one or more therapeutic compounds is 1:20, 1:15, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, or a range including or between any two of the aforementioned ratios, including its fractional increment (e.g., 2:1 to 10:1, 4:1 to 7:1, 4.5:1 to 6.5:1, etc.). In a specific embodiment, nucleic acid fragments are compounded with one or more therapeutic compounds at a weight / weight ratio of about 6:1. The size of the therapeutic agent / nucleic acid nanoparticle can also be controlled according to the concentration of the starting material, reaction parameters (e.g., temperature, time, etc.) and the addition of reagents (e.g., surfactants, salts, etc.). In a specific embodiment, the therapeutic / nucleic acid nanoparticle has a size of about 10 nm, 12 nm, 14 nm, 15 nm, 16 nm, 18 nm, 20 nm, 22 nm, 24 nm, 25 nm, 26 nm, 28 nm, 30 nm, 32 nm, 34 nm, 35 nm, 36 nm, 38 nm, 40 nm, 42 nm, 44 nm, 45 nm, 46 nm, 48 nm, 50 nm, 52 nm, 54 nm, 55 nm, 56 nm, 58 nm, 60 nm, 62 nm, 64 nm, 65 nm, 66 nm, 68 nm, 70 nm, 72 nm, 74 nm, 75 nm, 76 nm, 78 nm, 80 nm, 82 nm, 84 nm, 85 nm, 86 nm, 88 nm, 90 nm, 92 nm, 94 nm, 95 nm, 96 nm, 98 nm, 100 nm, 101 nm, 102 nm, 103 nm, 104 nm, 105 nm, 106 nm, 107 nm, 108 nm, 109 nm, 110 nm, 111 nm, 112 nm, 113 nm, 114 nm, 115 nm, 116 nm, 117 nm, 118 nm 400nm, 410nm, 420nm, 430nm, 440nm, 450nm, 460nm, 470nm, 480nm, 490nm, 500nm, or a range including or between any two of the above ratios, including fractional increments thereof (e.g., 20nm to 200nm, 50nm to 100nm, etc.). In a specific embodiment, the therapeutic agent / nucleic acid nanoparticle is about 70 nm in size.Nanoparticles can have any shape, including common spheres, ovoids, cubes, hexagons, prisms, rods, spirals, triangles, stars, or irregular shapes.
[0065] In certain embodiments, the present invention provides a pharmaceutical composition comprising the therapeutic / nucleic acid nanoparticles disclosed herein. The pharmaceutical composition can be formulated into a form suitable for administration to a subject, including the use of carriers, excipients, additives or adjuvants. Commonly used carriers or adjuvants include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, lactoprotein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohol, glycerol and polyols. Intravenous carriers include liquids and nutritional supplements. Preservatives include antimicrobial agents, antioxidants, chelating agents, cryoprotectants and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, nontoxic excipients, including salts, preservatives, buffers, etc., for example, as described in Remington's Pharmaceutical Sciences, 15th ed., Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed., Washington: American Pharmaceutical Association (1975), the contents of which are incorporated herein by reference. The pH and exact concentration of the various ingredients in the pharmaceutical composition are adjusted according to conventional techniques in the art. Reference is made to Goodman and Gilman's "Pharmacological Basis of Therapeutics" (7th edition).
[0066] Whether local or systemic, the pharmaceutical composition disclosed in the present invention can be administered in a therapeutically effective amount. As used in the present invention, "administering a therapeutically effective amount" is intended to include a method of administering or applying the pharmaceutical composition disclosed in the present invention to a subject, which allows the composition to exert its expected therapeutic efficacy. The therapeutically effective amount depends on factors such as the degree of infection of the subject, the age, sex and weight of the individual. The dosage regimen can be adjusted to provide the best therapeutic response. For example, the administration can be divided into several times a day, or the dosage can be reduced proportionally according to the urgency of the treatment situation.
[0067] The pharmaceutical composition can be administered in a convenient manner, for example, by injection (for example, subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal administration or rectal administration. Depending on the route of administration, the pharmaceutical composition can be coated with materials to protect the pharmaceutical composition from the damage of enzymes, acids and other natural conditions that may inactivate the pharmaceutical composition. The pharmaceutical composition can also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycol and mixtures thereof and oils. Under common storage and use conditions, these preparations may contain preservatives to prevent the growth of microorganisms.
[0068] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (if soluble in water) or dispersions and sterile powders for the extemporaneous preparation of sterile injection solutions or dispersions. The composition is usually sterile and fluid to the extent that it is easy to inject. Generally, the composition is stable under production and storage conditions and can resist contamination by microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, including, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.), suitable mixtures thereof and vegetable oils. For example, appropriate fluidity can be maintained by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. The action of microorganisms is prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, isotonic agents, such as sugars, polyols, such as mannitol, sorbitol or sodium chloride, are used in the composition. Prolonged absorption of injectable compositions can be achieved by including an agent that delays absorption in the composition, such as aluminum monostearate and gelatin.
[0069] According to the need, the pharmaceutical composition of the required amount is mixed with an appropriate solvent of one or more of the ingredients listed above, followed by filtration sterilization, and sterile injection solutions can be prepared. Usually, dispersions are prepared by incorporating the pharmaceutical composition into a sterile carrier, which contains a basic dispersion medium and other ingredients from the above list as required.
[0070] The pharmaceutical composition can be administered orally, for example, with an inert diluent or an absorbable edible carrier. The pharmaceutical composition and other ingredients can also be loaded into hard or soft shell gelatin capsules, compressed into tablets, or directly incorporated into the diet of the subject. For oral therapeutic administration, the pharmaceutical composition can be combined with excipients and used in the form of absorbable tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, etc. Such compositions and preparations should contain at least 1% by weight of the active compound. Of course, the percentage of the composition and preparation can be conveniently varied between about 5% to about 80% of the unit weight.
[0071] Tablets, lozenges, pills, capsules, etc. may also contain the following: binders, such as glacanth gum, gum arabic, corn starch or gelatin; excipients such as dicalcium phosphate; disintegrants, such as corn starch, potato starch, alginic acid, etc.; lubricants, such as magnesium stearate; and sweeteners such as sucrose, lactose or saccharin, or flavorings such as mint, wintergreen oil or cherry flavoring. When the dosage unit form is a capsule, it may contain a liquid carrier in addition to the above-mentioned types of materials. Various other materials may be used as coatings or otherwise change the physical form of the dosage unit. For example, tablets, pills or capsules may be coated with shellac, sugar or both. Syrups or elixirs may contain the agent, sucrose as a sweetener, methylparaben and propylparaben as preservatives, dyes and flavorings such as cherry or orange flavoring. Of course, any material used to prepare any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amount used. Additionally, the pharmaceutical compositions may be incorporated into sustained-release preparations and formulations.
[0072] Thus, "pharmaceutically acceptable carrier" is intended to include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except in the case where any conventional media or agents are incompatible with the pharmaceutical composition, their use in therapeutic compositions and methods of treatment is also contemplated. Supplementary active compounds may also be incorporated into the composition.
[0073] Formulating parenteral compositions in dosage unit form is highly advantageous for ease of administration and uniformity of dosage. As used herein, "dosage unit form" refers to physically discrete units suitable as single doses for subjects to be treated; each unit containing a predetermined amount of the pharmaceutical composition is calculated to produce the desired therapeutic effect in association with the desired pharmaceutical carrier. The specifications for the dosage unit forms disclosed herein are related to the characteristics of the pharmaceutical composition and the specific therapeutic effect to be achieved.
[0074] For convenient and effective administration, an effective amount of the main pharmaceutical composition is compounded with a suitable pharmaceutically acceptable carrier in an acceptable dosage unit. In the case where the composition contains auxiliary active ingredients, the dosage is determined by referring to the conventional dosage and administration method of the ingredients.
[0075] In a specific embodiment, the therapeutic agents / nucleic acid nanoparticles disclosed herein can be administered in combination with anticancer agents known in the art to treat a subject with cancer. The therapeutic agents / nucleic acid nanoparticles disclosed herein can be administered simultaneously or sequentially with an anticancer agent to treat a subject with cancer. The use of the therapeutic agents / nucleic acid nanoparticles disclosed herein with anticancer agents provides a multimodal therapy that provides a more effective cancer treatment method compared to the use of an anticancer agent alone or the use of a therapeutic agent / nucleic acid nanoparticle alone. Examples of anticancer agents that can be used with the therapeutic agents / nucleic acid nanoparticles disclosed herein include, but are not limited to, alkylating agents, such as thiotepa and Cyclophosphamide; alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridine derivatives, such as benzodepa, carboquinone, meturedopa, and uredopa; ethylenimine and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolomelamine; acetylspermine; etogenins (e.g., bullatacin and bullatacinone); camptothecins (including the synthetic analogue topotecan); bryostatin; carlistatin, CC-1065 (including synthetic analogues of adolesin, carzeresin and biszeresin); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycins (including synthetic analogues KW-2189 and CB1-TM1); cypermethrin; cypermethrin; cypermethrin; spongestatin; nitrogen mustards, such as chlorambucil, naphthyl mustard, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine hydrochloride, oxide hydrochloride), melphalan, nembice, phenylephrine, prednimustine, trorene, uracil mustard; nitrosoureas such as carmustine, chlorozostatin, fotemustine, lomustine, nimustine, and ranimustine; vinca alkaloids; epipodophyllotoxins; antibiotics such as the enediyne antitumor antibiotics (e.g., calicheamicins, particularly calicheamicin gamma and calicheamicin omegall); L-aspartame; anthracenedione-substituted ureas; methylhydrazine derivatives; dynemicins, including dynemicin A; bisphosphonates such as clodronate; an esperamicin and the neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores)), aclarubicin, actinomycin, anthramycin, azaserine, bleomycin, actinomycin C, karanomycin, carminomycin, chromophores, actinomycin D, daunorubicin, detoxibacin, 6-diazo-5-oxo-L-norleucine, Doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and antimetabolites), epirubicin, esorubicin, idarubicin, mexilomycin, mitotoxins such as mitotoxin C, mycophenolic acid, nogamycin, olivetomycin, peplomycin, methyl mitomycin (potfiromycin), puromycin, triferric doxorubicin, rhodorubicin, Streptozotocin, streptozotocin, tuberculocidin, ubenimex, netastatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetapterin; purine analogs such as fludarabine, 6-azauridine, carmofur, cytarabine, dideoxyuracil, doxifluridine, enocitabine, floxuridine; androgens such as dimethyltestosterone, methylandrostanolone, cyclothiocarb, melastosane, testosterone; antiadrenal hormones such as anlutamide, mitotane, trilostane; folic acid supplements such as flufenamic acid (frolinic acid) acid); acetoglucuronide; aldehyde phosphamide glycoside; aminovaleric acid; eniluracil; amsacrine; amustine; bisantrine; edatrexate; defofamine; colcemid; diazocrine; ornithine; hydroxypyrrolidone acetate; epothilone; ethoxydimidine; gallium nitrate; hydroxyurea; mushroom polysaccharide; lonidamine; maytansine compounds such as maytansine and ansamitocin; mitoxantrone; mitoxantrone; mopidanmol; diamine nitracrine; pentostatin; methamine nitrogen mustard; pirarubicin; loxoquinone; podophyllic acid; 2-ethylpyrazine; methylbenzylhydrazine; Polysaccharide complex (JHS Natural Products, Eugene, Oreg.); azoxystrobin; rhizobactin; sizofran; spirogermanamine; saxosporic acid; triazoquinone, 2,2'-trichlorotiiethylamine; trichothecenes (especially T-2 toxin, sporebactin A, baculomycin A, and sporebactin); urethane; vinblastine amide; dacarbazine; mannosamine; dibromomannitol; dibromodulanol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes such as Paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), Cremophor-free albumin-engineered paclitaxel nanoparticle formulation (American Pharmaceutical Partners, Schaumberg, Ill.) and (docetaxel) (Rhone-Poulenc Rorer, Antony, France); chlorambucil; (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; (Changchunrelbine); novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS2000; difluoromethylornithine (DFMO); retinoids such as retinoic acid; capecitabine; folinic acid (LV); irinotecan; adrenocortical inhibitors; adrenocortical steroids; progestins; estrogens; androgens; gonadotropin-releasing hormone analogs and pharmaceutically acceptable salts, acids or derivatives of any of the above. Anticancer agents also include antihormonal agents that regulate or inhibit the effects of hormones on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs) including, for example, tamoxifen (including Tamoxifen), raloxifene, droloxifene, 4-hydroxytamoxifen, trifluoxifene, raloxifene hydrochloride (droloxifene), 4-hydroxytamoxifen, droloxifene, keoxifene, LY117018, ornoprostil and faloton-toremifene, aromatase inhibitors that inhibit the aromatase enzyme that regulates estrogen production in the adrenal glands, for example, 4(5)-imidazoles, anilutamide, Megestrol acetate, Exemestane, formestane, fadrozole, Vorozole, Letrozole and Anastrozole, and antiandrogens such as flunitramide, nilutamide, bicalutamide, leuprolide and goserelin, and troxacitabine (a 1,3-dioxolane nucleoside cytosine analog), antisense oligonucleotides, especially those that inhibit the expression of genes in signaling pathways associated with aberrant cell proliferation, such as PKC-α, Ralf and H-Ras; ribozymes, such as VEGF-A expression inhibitors (such as angiotensin ribozymes) and HER2 expression inhibitors; vaccines, such as gene therapy vaccines, for example, vaccine, Vaccines and vaccine, rJL-2, Topoisomerase 1 inhibitors, rmRH; antibodies such as trastuzumab; and pharmaceutically acceptable salts, acids or derivatives of any of the above. In a specific embodiment, the therapeutic agent / nucleic acid nanoparticle disclosed in the present invention is used in combination with one or more anticancer agents selected from cyclophosphamide, tamoxifen, tegafur, paclitaxel, apatinib, cisplatin, docetaxel, 5-fluorouracil, capecitabine, carboplatin, vinorelbine, capecitabine, gemcitabine, ixabepilone, eribulin, ifosfamide, rituximab, vincristine, prednisone, bleomycin and dacarbazine.
[0076] In order to be used for treatment or biological application described in the present invention, the present invention also describes test kits and articles. Such test kits may include carriers, packaging or containers that are separated to accommodate one or more containers, such as vials, tubes, etc., each of which contains one of the separation elements used in the method described in the present invention. Suitable containers include, for example, bottles, vials, syringes and test tubes. Containers may be made of various materials, such as glass or plastics.
[0077] For example, the container may contain one or more therapeutic agents / nucleic acid nanoparticles described herein, optionally in combination or compound with another agent disclosed herein (e.g., mRNA and / or ssRNA). Optionally, the container has a sterile access port (e.g., the container may be an intravenous solution bag or a vial with a stopper pierceable by a hypodermic needle). Such kits may optionally include an identifying description or label or instructions related to their use in the methods described herein.
[0078] Kits typically include one or more additional containers, each container having one or more of various materials (e.g., reagents, optionally in concentrated form, and / or devices) that are desirable from a commercial and user perspective for use of the compounds of the invention. Non-limiting examples of such materials include, but are not limited to, buffers, diluents, filters, needles, syringes; carriers, packages, containers, vials, and / or test tube labels listing the contents and / or instructions for use, and package inserts with instructions for use. A set of instructions is also typically included.
[0079] The label can be on the container or associated with the container. The label can be on the container when the letters, numbers or other characters forming the label are attached, molded or etched into the container itself. When the label is present in a container or carrier that also holds the container, the label can be associated with the container, such as as a package insert. The label can be used to indicate that the contents are used for specific treatment applications. The label can also indicate the instructions for use of the contents, such as the method described in the present invention. These other therapeutic agents can be used in the amount shown in, for example, the physician's desk reference (PDR), or by the amount determined otherwise by those of ordinary skill in the art.
[0080] The present disclosure further provides that the methods and compositions described herein may be further defined by the following aspects (Aspects 1 to 29):
[0081] 1. A composition comprising one or more therapeutic compounds complexed with nucleic acid fragments to form nanoparticles, wherein the one or more therapeutic compounds are small molecules capable of associating or binding to DNA or RNA.
[0082] 2. The composition of aspect 1, wherein the nucleic acid fragment is complexed with the one or more therapeutic compounds in a weight / weight ratio of 2:1 to 10:1.
[0083] 3. The composition of aspect 1 or aspect 2, wherein the nucleic acid fragment is complexed with the one or more therapeutic compounds in a weight / weight ratio of 4:1 to 7:1.
[0084] 4. The composition of any of the preceding aspects, wherein the nucleic acid fragments are complexed with the one or more therapeutic compounds in a weight / weight ratio of about 6:1.
[0085] 5. The composition according to any one of the preceding aspects, wherein the size of the nanoparticles is between 20 nm and 200 nm.
[0086] 6. The composition according to any one of the preceding aspects, wherein the size of the nanoparticles is 50 nm to 100 nm.
[0087] 7. The composition of any of the preceding aspects, wherein the one or more therapeutic compounds comprises an anthracycline, anthracenedione, a camptothecin, a podophyllin, a minor groove binder, bleomycin and / or actinomycin D.
[0088] 8. The composition according to any one of the preceding aspects, wherein the one or more therapeutic compounds comprises aclarubicin, doxorubicin, daunorubicin, idarubicin, epirubicin, amrubicin, pirarubicin, valrubicin and / or zorubicin.
[0089] 9. The composition of any one of the preceding aspects, wherein the one or more therapeutic compounds comprises doxorubicin.
[0090] 10. The composition of any one of the preceding aspects, wherein the one or more therapeutic compounds comprises mitoxantrone, topotecan, etoposide, teniposide, bleomycin, actinomycin D and / or duocarmycin A.
[0091] 11. The composition of any of the preceding aspects, wherein the nucleic acid fragment comprises a ligand that targets the nanoparticle to a specific cell, tissue, organ or tumor.
[0092] 12. The composition of any of the preceding aspects, wherein the nucleic acid fragments comprise fragments of naturally occurring DNA, RNA and / or DNA-RNA hybrids.
[0093] 13. The composition of any one of the preceding aspects, wherein the nucleic acid fragments comprise chemically synthesized DNA, RNA and / or DNA-RNA hybrids of different nucleotide lengths.
[0094] 14. The composition of any one of the preceding aspects, wherein the RNA has been modified to replace the 2' ribose hydroxyl group with an -O-alkyl or halide.
[0095] 15. The composition of any one of the preceding aspects, wherein the nucleic acid fragment is a DNA fragment.
[0096] 16. The composition of any one of the preceding aspects, wherein the DNA fragments are from salmon DNA.
[0097] 17. The composition of any preceding aspect, wherein the nucleic acid fragments are 20 nt to 10,000 nt in length.
[0098] 18. The composition of any preceding aspect, wherein the nucleic acid fragment has a length of 50 nt to 2,000 nt.
[0099] 19. The composition of any of the preceding aspects, wherein the composition comprises nanoparticles of one or more therapeutic compounds complexed with DNA fragments ranging from 50 nt to 2,000 nt in length.
[0100] 20. The composition of any one of the preceding aspects, wherein the one or more therapeutic compounds are selected from aclarubicin, doxorubicin, daunorubicin, idarubicin, epirubicin, amrubicin, pirarubicin, valrubicin and / or zorubicin.
[0101] 21. The composition of any one of the preceding aspects, wherein the one or more therapeutic compounds is doxorubicin.
[0102] 22. A pharmaceutical composition comprising the composition of any one of the preceding aspects and a pharmaceutically acceptable carrier, diluent and / or excipient.
[0103] 23. The pharmaceutical composition of aspect 22, wherein the pharmaceutical composition is formulated for parenteral delivery.
[0104] 24. A method of treating a subject suffering from cancer in need thereof, comprising: administering to the subject an effective amount of the pharmaceutical composition of aspect 22 or aspect 23.
[0105] 25. The method of aspect 24, wherein the cancer is selected from acute lymphocytic leukemia, acute myeloid leukemia, osteosarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, kidney cancer, multiple myeloma, neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thymoma, thyroid cancer, transitional cell bladder cancer, uterine sarcoma, Wilms' tumor and Waldenstrom's macroglobulinemia.
[0106] 26. A method of treating a human subject suffering from cancer in need thereof, comprising: administering to the subject an effective amount of the composition of any one of aspects 1 to 21.
[0107] 27. The method of aspect 26, wherein the cancer is selected from acute lymphocytic leukemia, acute myeloid leukemia, osteosarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, kidney cancer, multiple myeloma, neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thymoma, thyroid cancer, transitional cell bladder cancer, uterine sarcoma, Wilms' tumor and Waldenstrom's macroglobulinemia.
[0108] 28. The method of aspect 26 or aspect 27, wherein the method further comprises administering to the subject one or more anticancer agents selected from angiogenesis inhibitors, tyrosine kinase inhibitors, PARP inhibitors, alkylating agents, vinca alkaloids, anthracyclines, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, aromatase inhibitors, mTor inhibitors, retinoids and HDAC inhibitors.
[0109] 29. The method of any one of aspects 26 to 28, wherein the method further comprises administering to the subject one or more anticancer agents selected from mitoxantrone, topotecan, etoposide, teniposide, bleomycin, actinomycin D and duocarmycin A. DETAILED DESCRIPTION
[0110] The following examples are intended to illustrate, but not to limit, the present invention. Although they are typical of those that may be used, other methods known to those skilled in the art may be used instead.
[0111] Materials. Doxorubicin (DOX) and ethidium bromide were purchased from Thermo Fisher Scientific (Waltham, MA). Deoxyribonucleic acid (DNA) (50-2000 nucleotide fragments, MW range 16.88 kDa-1350 kDa) was provided by PharmaResearch Products Ltd (Seong Nam, Korea). 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Millipore Sigma (Burlington, MA). ULYSIS TM Alexa Fluor TM The 488 Nucleic Acid Labeling Kit was purchased from Thermo Fisher Scientific. Nucleic acid labeling kit, 5 was purchased from MirusBio. EL4 cells (ATCC, Rockville, MD) were cultured in Dulbecco's modified Eagle's medium (DMEM) (MediaTech, Manassas, VA) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA) and 1% antibiotics (100 units / mL penicillin; 100 μg / mL streptomycin) (Gibco, Grand Island, NY). All materials were used as purchased.
[0112] DOX quenching of DNA. To optimize encapsulation efficiency, quenching studies were performed. Fluorescence spectra were first measured for DNA:DOX ratios between 1-100, and then for DNA:DOX ratios between 1-10. Excitation was performed at 490nm and emission was performed at 590nm. Fluorescence was read using a xenon laser and a Synergy H1 hybrid multimode reader (Biotek Instruments, Winooski, VT).
[0113] Preparation of DOX / DNA nanoparticles. Briefly, DNA was added to DOX at a ratio of 6:1 w / w. Time was allocated for self-assembly. Finally, phosphate buffered saline (PBS) was added to the mixture and allocated for another 30 min for ionic stabilization of the complex.
[0114] An equal volume of DNA was pipetted into an equal volume of DOX and mixed up and down. The reactants and reactions were maintained at 70 ° C. Then, it was allowed to stand for 15 minutes to allow self-assembly. Then, an equal volume of 2X PBS was pipetted into the reaction vessel and mixed by blowing up and down. After standing for 30 minutes, further experiments were performed using DOX / DNA nanoparticles. For small volumes below 25 mL, 96-well plates were used. For large volumes exceeding 25 mL, round-bottom flasks were used and mixing was induced by a magnetic stirring bar rotating at 500 RPM on a multi-plate stirrer (IKA Works, Inc., Wilmington, NC). In this embodiment, DNA was added dropwise to DOX using a glass pipette. In order to verify the formation of nanoparticles, DOX / DNA images were taken using a transmission electron microscope (TEM).
[0115] Transmission electron imaging of DOX / DNA and DNA. An equal volume of DNA was pipetted into an equal volume of DOX and mixed up and down. The reactants and reactions were maintained at 70 ° C. Then, it was allowed to stand for 15 minutes to allow self-assembly. Then, an equal volume of 2X PBS was pipetted into the reaction vessel and mixed up and down. A 30-minute standing time was provided before further experiments with DOX / DNA nanoparticles. For small volumes below 25 mL, a 96-well plate was used. For large volumes exceeding 25 mL, a round-bottom flask was used and mixing was induced by a magnetic stirring bar rotating at 500 RPM on a multi-plate stirrer (IKA Works, Inc., Wilmington, NC). In this embodiment, DNA was added dropwise to DOX using a glass pipette. In order to verify the formation of nanoparticles, DOX / DNA images were taken using a transmission electron microscope (TEM).
[0116] DOX / DNA solution (10 μL) was dropped onto carbon-coated grids (Thermo Fisher Scientific) and dried overnight at room temperature. The morphology and size of the nanoparticles were observed using a JEOL 2800 transmission electron microscope (JEOL, Peabody, MA) at 200 kV.
[0117] DNA degradation in 10% FBS / PBS. A 1% (w / v) agarose gel in 1X Tris acetate EDTA (TAE) containing 1 μg / mL ethidium bromide was used to describe the degradation of DNA in 10% FBS / PBS for 48 hours. DNA was incubated with PBS containing serum at 37°C for a period of time. Samples were stored at -20°C to stop nuclease digestion at each time point. DNA concentration = 100 μg / mL. The gel was run at 100 V for 40 minutes and the DNA was imaged on a UV transilluminator (Fotodyne, Heartland, WI).
[0118] Binding Kinetics. The binding kinetics of DOX to DNA were measured by observing the fluorescence of DOX / DNA based on the DOX concentration. The fluorescence of DOX / DNA was measured as DOX increased. DNA was kept constant at 400 μg / mL concentration. Fluorescence was measured using a multimode reader. The binding kinetics of DOX to DOX / DNA were studied in PBS, PBS with serum, or FBS.
[0119] EL4 cytotoxicity. EL4 cells (ATCC, Rockville, MD) were plated in 96-well plates at 10k cells per well. Plated cells were treated three times with DOX or DOX equivalents ranging from 0.001 μg / mL to 10 μg / mL for 24, 48, or 72 hours, and then cell viability was analyzed by MTT assay. Cells were cultured at 37°C, 5% CO2, and 100% humidity. Absorbance was read at 571 nm.
[0120] Endocytosis inhibition. DOX uptake by DOX- or DOX / DNA-treated EL4 was measured using flow cytometry or fluorescence spectroscopy after exposure to the inhibitors NaN3 (120 mM), PS2 (12 μg / mL), Filipin III (5 μg / mL), CPZ (20 μM), EIPA (20 μg / mL), or 4°C. Briefly, cells were pretreated with inhibitors for 15 min before treatment with DOX or DOX / DNA for 1 h. Cells containing DOX or DOX / DNA were counted by flow cytometry as yellow fluorescence, and cells containing DOX / DNA were counted by fluorescence spectroscopy. easyCyte TM Fluorescence was measured by flow cytometer (Millipore Sigma, Burlington, MA) or multimode reader (Biotek Instruments, Winooski, VT).
[0121] Confocal imaging. EL4 cells were first placed on 35 mm Ibidi μ-Dish (Ibidi USA Inc., Fitchburg, WI) plates at 200 k cells per ml. Then, the nuclei were stained and incubated for 15 minutes. The cells were spun and washed with DPBS before being treated with DOX / DNA-Cy5 for 3 hours. Finally, the cells were spun at 500 × g and washed with DPBS before being placed in DMEM, and the cells were imaged live using a Leica TCS SP8 confocal laser scanning microscope (Leica Microsystems, Buffalo Grove, IL).
[0122] In vivo studies. All animal studies were performed using IACUC-approved procedures. EL4 tumors were established by subcutaneous injection of 1E6 EL4 cells (present in approximately 100 μL PBS) into the right hind flank of 6-12 week old female C57BL / 6 / 027 mice (Charles River Laboratories, Wilmington, MA, USA). Once the tumor was 2 mm visible and measurable, the mice were dosed by tail vein injection. Tumor size was measured using a digital caliper, and tumor volume was calculated using the following formula: V = W 2 L / 2, where V is the tumor volume, W is the tumor width, and L is the tumor length. Mice were given free access to food and water.
[0123] Pharmacokinetics. Pharmacokinetic studies were conducted in EL4 tumor-bearing C57BL / 6 mice (female, 6-8 weeks old) that received 20 mg / kg DOX or 20 mg / kg DOX / DNA intravenous injections, n = 3. Blood samples were collected from the saphenous vein of the mice at each time point, centrifuged in serum collection tubes, and the resulting supernatant was analyzed for DOX fluorescence in acidified ethanol using a multimode reader.
[0124] Hematotoxicity and liver enzyme groups. The mice used in this study were 6-12 week old female C57BL / 6 / 027 mice (Charles River Laboratories, Wilmington, MA, USA). The mice were dosed by tail vein injection. After 24 hours, complete blood count (CBC) and liver enzyme levels were determined. CBC blood was collected through the saphenous vein, mixed with EDTA, and analyzed for white blood cells (WBC), red blood cells (RBC), hemoglobin (Hgb), platelets (Plt), and hematocrit (HCT) using a hematology analyzer. For the liver enzyme group, serum was separated from the blood and sent to IDEXX Laboratories, Inc. (Westbrook, ME) for alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin analysis.
[0125] Binding Kinetics. The binding kinetics of DOX to DNA were measured by observing the fluorescence of DOX / DNA based on the DOX concentration. The fluorescence of DOX / DNA was measured as [DOX] increased. [DNA] was maintained at a constant level of 400 μg / mL. Fluorescence was measured using a multimode reader. The binding kinetics of DOX to DOX / DNA were studied in PBS, PBS with serum, or FBS.
[0126] Biodistribution. DOX accumulation in organs and tumors was measured 1, 3, 6, and 12 hours after intravenous administration of 20 mg / kg DOX or DOX / DNA (20 mg / kg DOX equivalent) to EL4 tumor-bearing C57BL / 6 mice (female, 6-8 weeks old), n=5. Briefly, organs and tumors were harvested, cryogenically frozen, and homogenized in acidified ethanol before centrifugation. The resulting supernatant was analyzed for DOX fluorescence using a multimode reader.
[0127] Acute toxicity. Acute toxicity was observed 24 hours after injection in C57BL / 6 mice (female, 6-8 weeks) at doses ranging from 10 to 40 mg / kg DOX or DOX equivalents, n=7.
[0128] Tumor growth and survival. Tumor growth and survival of EL4 tumor-bearing mice (6-12 week old female mice) were followed regularly for 30 days after intravenous administration of a range of doses of DOX, DOX / DNA or DOXIL, n=5. The initial tumor challenge consisted of subcutaneous injection of 1E6 EL4 cells into the right hind flank of the mice. When tumor growth of 2 mm was measurable, the drug was administered via the tail vein. Mice were euthanized when tumors exceeded 15 mm, tumor lesions appeared, or body weight dropped to less than 75% of initial body weight.
[0129] Repeated dosing tumor growth and survival. After 22 days of intravenous treatment with 20 mg / kg dose of DOX, DOX / DNA or DOXIL on the initial day 0, the tumor growth, weight and survival rate of EL4 tumor-bearing mice (6 weeks, female) were tracked. Subsequently, on the 7th and 14th days, 20 mg / kg doses of DOX, DOX / DNA or DOXIL were administered, n=5. The initial tumor challenge consisted of subcutaneous injection of 1E6 EL4 cells into the right hind flank of the mouse. When tumor growth of 2 mm could be measured, it was administered through the tail vein. When the tumor exceeded 15 mm, tumor lesions appeared, or the body weight dropped to less than 75% of the initial body weight, the mice were euthanized.
[0130] Physical properties of DOX / DNA complexes. DOX loading capacity and efficiency of DNA: DOX quenching studies were performed using DNA to evaluate the loading capacity and encapsulation efficiency of DOX / DNA nanoparticles (see Figure 1 The DOX / DNA loading and encapsulation efficiency were determined to be ∼14% and ∼88%, respectively. First, the fluorescence spectra of DNA:DOX ratios between 1 and 100 were measured ( Figure 1 , top), and then the fluorescence spectra of DNA:DOX ratios between 1 and 10 were measured using 490 nm excitation ( Figure 1 , lower figure). It was determined that the most favorable weight ratio of DNA to DOX was 6:1.
[0131] Size characterization of DOX / DNA complexes. Transmission electron microscopy was used to evaluate the size and morphology of DOX / DNA. DOX / DNA nanoparticles were prepared as described previously and then in water (see Figure 2 ) or PBS (see Figure 3 ) was diluted to a concentration of 1 μg / mL (DOX equivalent) in . The solution was allowed to stand for another 30 minutes and then dropped onto a carbon grid for TEM imaging. Transmission electron microscopy of DOX / DNA showed that the nanoparticle size was approximately 70nm. These characterization studies show that the particles can carry chemotherapeutic agents such as DOX, and the size characterization specifically demonstrates the ability of these particles to reach cancer cells.
[0132] Long-term storage potential of DOX / DNA nanoparticles. Briefly, DOX / DNA was prepared in PBS, diluted with H2O, lyophilized overnight, and then reconstituted with H2O and subsequently imaged. Final [DNA] = 6 μg / mL, final [DOX] = 1 μg / mL. The stability of DOX / DNA was largely unaffected by the lyophilization process (see Figure 4-6 ).
[0133] DNA stability in water and PBS. DNA was prepared in PBS, diluted in H2O, and imaged. Final [DNA] = 6 μg / mL. DNA was essentially stable in water or PBS (see Figure 7-8 ).
[0134] DNA degradation in 10% FBS / PBS. To determine the stability of DNA to serum exposure, DNA (100 μg / mL) was incubated with serum-containing PBS at 37°C for 0 to 48 h. Samples were stored at -20°C to stop nuclease degradation at each time point. DNA was degraded by serum in a time-dependent manner (see Fig. 9 ). Nucleases in serum-containing medium may contribute to DNA degradation. It can be inferred that the delayed release of DOX is caused by the degradation of DNA over time in 10% fetal bovine serum (FBS).
[0135] Cytotoxicity of DOX / DNA complexes in vitro at 24, 48, and 72 hours. A study was conducted to observe the in vitro cytotoxicity of DOX / DNA in EL4 cells at 24 hours (left curve), 48 hours (middle curve), and 72 hours (right curve). EL4 cells were treated three times using a series of concentrations for 24, 48, and 72 hours, and then cell viability was analyzed by MTT assay. At 24h of incubation, DOX / DNA was approximately 3.5-fold less cytotoxic than DOX to these cells, as reported by IC 50 Values shown: DOX / DNA IC 50=1.143μg / mL or 2.1μM, DOX IC 50 = 0.313 μg / mL or 0.576 μM (see Fig.10 ). Compared with DOX, DOX / DNA showed similar cytotoxicity to these cells at 48 and 72 h of culture, as reported in the IC 50 Values shown: DOX / DNA IC at 48h 50 =0.072μg / mL, DOX IC 50 =0.093μg / mL, or at 48h, DOX / DNAIC 50 =0.055 μg / mL, DOX IC 50 =0.048 μg / mL. This result, combined with the 24-hour cytotoxicity data, indicates that the release of DOX from DOX / DNA is delayed. In addition, the results show that the nanoparticles exhibit less toxicity compared to their free small molecule counterparts.
[0136] In vivo pharmacokinetics of DOX / DNA. Results of a pharmacokinetic study of EL4 tumor-bearing C57BL / 6 mice treated with 20 mg / kg DOX or 20 mg / kg DOX equivalent DOX / DNA intravenously (see Fig.11 These mice were female mice aged 6-8 weeks. 1 / 2 Compared with mice treated with DOX / DNA, DOX / DNA had a longer blood circulation half-life in EL4 tumor-bearing C57BL / 6 mice (DOX / DNA: T 1 / 2 =75min), n=3. DOX was absorbed by tissues within ~15 minutes (as shown by the initial steep slope of the curve), and then a profile more like liver and kidney clearance was observed. However, DOX / DNA showed a much lower tissue absorption curve that lasted for 1 hour. From the above results, it can be inferred that DNA enhances the circulation of DOX and DOX protection / shielding. Afterwards, features indicative of liver and kidney clearance were observed. Therefore, the drug delivery system of the present disclosure alters the dissolution and absorption of doxorubicin, potentially allowing for sustained release of the active agent.
[0137] DOX / DNA dissociation kinetics in vitro. The binding kinetics of DOX to DNA were measured by observing the fluorescence of DOX / DNA based on the DOX concentration. The fluorescence of DOX / DNA was measured as [DOX] increased. [DNA] was maintained at a constant level of 400 μg / mL. The fluorescence in was measured using a multimode reader. The binding kinetics of DOX to DOX / DNA were studied in PBS, PBS with serum, or FBS. The DOX dissociation of DOX / DNA increased with increasing serum content and time (see Figure 12-13). This data is consistent with the data from DNA degradation analysis. The K of DOX dissociation from DOX / DNA in PBS, 10% FBS, 25% FBS, 50% FBS, and FBS was d The values were calculated to be 76.8 nM, 152.7 nM, 317.7 nM, 565.1 nM and 1329.7 nM, respectively. This experiment clearly showed that FBS releases DOX from DNA.
[0138] Study on DOX release from DOX / DNA. Cumulative release of DOX from DOX / DNA was performed in 100% PBS, 10% FBS / PBS, 25% FBS / PBS, 50% FBS / PBS, or 100% FBS for 72 h. When FBS was used, the highest DOX release from DOX / DNA was found (see Fig.14 ). This, combined with the data obtained from the binding kinetics experiments, suggests that DOX is released from DOX / DNA over time, depending on the amount of serum in the culture medium. At least according to this model, most of the DOX should be released from the nanoparticles within 72 hours.
[0139] Complete blood count and liver enzymes of DOX / DNA and DOX groups. Complete blood count and liver enzyme analysis were performed in C57BL / 6 mice receiving 20 mg / kg DOX, 20 mg / kg DOX equivalent of DOX / DNA, PBS or 120 mg / kg DNA, n=3. The mice used in this study were 6-12 week old female C57BL / 6 / 027 mice (Charles River Laboratories, Wilmington, MA, USA). Mice were dosed by tail vein injection. After 24 hours pi, complete blood count (CBC) and liver enzyme levels were measured. Blood was collected through the great saphenous vein, mixed with EDTA, and analyzed for white blood cells (WBC), red blood cells (RBC), hemoglobin (Hgb), platelets (Plt) and hematocrit (HCT) using a hematology analyzer. For the liver enzyme panel, 24 h pi serum was separated from the blood and sent to IDEXX Laboratories, Inc. (Westbrook, ME) for analysis of alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin. DOX had greater effects on circulating blood cells and liver enzymes compared with DOX / DNA and DOXIL. Based on these groups, the modulation of blood components and liver enzymes by DOX / DNA was significantly different from that by DOX alone (see Fig.15 ).
[0140] Biodistribution of DOX / DNA and DOX in vivo. DOX accumulation was characterized in organs and tumor tissues 1, 3, 6, and 12 h after intravenous administration of 20 mg / kg DOX, DOXIL (20 mg / kg DOX equivalent), or DOX / DNA (20 mg / kg DOX equivalent) to EL4 tumor-bearing C57BL / 6 mice (female, 6-8 weeks old). DOX accumulation in the lungs was lower in the DOX / DNA group, n = 5 (except DOXIL 12h, where n = 3) (see Figure 16-18 ). The greatest tumor accumulation of DOX was found in mice treated with DOX / DNA. Therefore, DOX / DNA improved drug delivery to the tumor site. In addition, DOX / DNA had less organ toxicity, especially in the lungs and spleen. This was also highlighted by the higher levels of DOX clearance by the liver and kidneys. Larger particles such as DOX / DNA allow for macrophage uptake and clearance from the lungs, so DOX has less lung toxicity when administered in the form of DOX / DNA.
[0141] Acute toxicity survival curves in C57BL / 6 mice. No acute toxicity was observed at 20 mg / kg or below, n=7. DOX-treated mice developed acute toxicity (cardiac arrest) at a dose of 40 mg / kg (see Fig.19 ). Therefore, DOX / DNA is safer than DOX. DOX / DNA has a larger therapeutic window than DOX. Regarding DOXIL, compared with DOXIL, the assembly process of DOX / DNA is simpler and the production efficiency is higher.
[0142] Effects of DOX, DOX / DNA, and DOXIL treatment on tumor growth and survival in the EL4-cancer model. To verify the safety and efficacy of this drug delivery system, tumor growth and survival of EL4-tumor-bearing mice were regularly followed for 30 days after intravenous treatment with a range of doses of DOX or DOX / DNA (2-3 month old female mice). In EL4-tumor-bearing C57BL / 6 mice (n=5), DOX / DNA slowed tumor growth and improved survival, superior to DOX treatment alone (see Fig. 20 ). When using the nanocarrier formulation, the 20 mg / kg dose showed prolonged survival and slowed tumor growth. Interestingly, in mice treated with 40 mg / kg DOX / DNA, complete tumor regression was observed until day 28. In addition, 60% of these mice survived to the end of the experiment. DOX / DNA treatment caused EL4 tumor-bearing C57BL / 6 mice (n=5) to lose weight in the high-dose treatment (see Fig.21). These results effectively demonstrate the ability of DNA to increase the maximum tolerated dose of DOX, in addition to its protective effect against systemic toxicity. Furthermore, DNA treatment alone was similar to PBS treatment, which highlights the safety of the drug delivery vehicle in this murine solid tumor model.
[0143] Endocytosis inhibition and effects on DOX / DNA and DOX uptake. The inhibitors CPZ (20 μM), Filipin III (5 μM), EIPA (20 μM) and their various combinations or 4°C were evaluated for their effects on DOX / DNA uptake in EL4 cells (see Fig. 22 ). Chlorpromazine (CPZ) is an inhibitor of the clathrin-dependent pathway. Filipin III is an inhibitor of the caveolin-dependent pathway. EIPA is an inhibitor of the macrophage uptake pathway. The concentrations selected for the assay were determined using a dose-response analysis of each inhibitor. It was found that cells took up DOX / DNA via both clathrin-dependent and caveolin-dependent pathways. Membrane fusion was also involved, as shown by the 4°C inhibition of DOX / DNA uptake.
[0144] DOX uptake in EL4 cells was examined using inhibitors. NaN3 (120 mM), PS2 (12 μg / mL), Filipin III (5 μg / mL), EIPA (20 μM) and 4°C. Uptake was measured using flow cytometry. Briefly, cells were primed with inhibitors for 15 min prior to 1 h of DOX treatment. Cells containing DOX were counted using flow cytometry using yellow fluorescence. Inhibition studies showed that, in contrast to DOX / DNA, DOX uptake was primarily via membrane fusion (see Fig.23 ).
[0145] Confocal imaging of EL4 cells treated with DOX / DNA shows the localization of the treatment in EL4 cells. CLSM images show that EL4 cells take up DOX / DNA over time (see Fig.24 ). The CLSM images also demonstrated the internalization of the nanoparticles, not just DOX.
[0146] Titrate DOX, DNA, and DOX / DNA using weak base. Prepare DOX, DNA, or DOX / DNA in an initial volume of 1 mL of water. The DOX equivalent is 600 μg / mL. Then, the pH is lowered to below 2 with 1 M HCl, and then the pH is adjusted higher with a small volume (100 μL or 20 μL) of 0.1 M NaOH. DOX, DNA, and DOX / DNA all show similar titration curves (see Fig.25 ).
[0147] Many embodiments have been described herein. However, it should be understood that various modifications may be made without departing from the spirit and scope of the present disclosure. Therefore, other embodiments are within the scope of the claims.
Claims
1. A composition comprising one or more therapeutic compounds complexed with nucleic acid fragments to form nanoparticles, characterized in that: The one or more therapeutic compounds are small molecules that are capable of associating or binding to DNA or RNA.
2. The composition according to claim 1, characterized in that The nucleic acid fragments are complexed with the one or more therapeutic compounds in a weight / weight ratio of 2:1 to 10:
1.
3. The composition according to claim 2, characterized in that The nucleic acid fragments are complexed with the one or more therapeutic compounds in a weight / weight ratio of 4:1 to 7:
1.
4. The composition according to claim 2, characterized in that The nucleic acid fragments are complexed with the one or more therapeutic compounds in a weight / weight ratio of about 6:
1.
5. The composition according to claim 1, characterized in that The size of the nanoparticles is 20 nm to 200 nm.
6. The composition according to claim 5, characterized in that The size of the nanoparticles is 50 nm to 100 nm.
7. The composition according to claim 1, characterized in that The one or more therapeutic compounds include anthracyclines, anthracenediones, camptothecins, podophyllins, minor groove binders, bleomycin and / or actinomycin D.
8. The composition according to claim 7, characterized in that The one or more therapeutic compounds include aclarubicin, doxorubicin, daunorubicin, idarubicin, epirubicin, amrubicin, pirarubicin, valrubicin, and / or zorubicin.
9. The composition according to claim 8, characterized in that The one or more therapeutic compounds include doxorubicin.
10. The composition according to claim 7, characterized in that The one or more therapeutic compounds include mitoxantrone, topotecan, etoposide, teniposide, bleomycin, actinomycin D and / or duocarmycin A.
11. The composition according to claim 1, characterized in that The one or more nucleic acid segments comprise a ligand that targets the nanoparticle to a specific cell, tissue, organ or tumor.
12. The composition according to claim 1, characterized in that The nucleic acid fragments include fragments of naturally occurring DNA, RNA and / or DNA-RNA hybrids.
13. The composition according to claim 1, characterized in that The nucleic acid fragments include chemically synthesized DNA, RNA and / or DNA-RNA hybrids of different nucleotide lengths.
14. The composition according to claim 13, characterized in that The RNA has been modified to replace the 2' ribose hydroxyl group with an -O-alkyl or halide.
15. The composition according to claim 1, characterized in that The nucleic acid fragment is a DNA fragment.
16. The composition according to claim 15, characterized in that The DNA fragment is derived from salmon DNA.
17. The composition according to claim 1, characterized in that The length of the nucleic acid fragment is 20 nt to 10,000 nt.
18. The composition according to claim 17, characterized in that The length of the nucleic acid fragment is 50 nt to 2,000 nt.
19. The composition according to claim 1, characterized in that The compositions comprise nanoparticles of one or more therapeutic compounds complexed with DNA fragments ranging from 50 nt to 2,000 nt in length.
20. The composition according to claim 19, characterized in that The one or more therapeutic compounds are selected from aclarubicin, doxorubicin, daunorubicin, idarubicin, epirubicin, amrubicin, pirarubicin, valrubicin and / or zorubicin.
21. The composition according to claim 20, characterized in that The one or more therapeutic compounds is doxorubicin.
22. A pharmaceutical composition comprising the composition according to any one of claims 1 to 21 and a pharmaceutically acceptable carrier, diluent and / or excipient.
23. The pharmaceutical composition according to claim 22, characterized in that The pharmaceutical composition is formulated for parenteral delivery.
24. A method of treating a subject having cancer in need of treatment, comprising: Administering an effective amount of the pharmaceutical composition of claim 22 to the subject.
25. The method of claim 24, wherein: The cancer is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, osteosarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, kidney cancer, multiple myeloma, neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thymoma, thyroid cancer, transitional cell bladder cancer, uterine sarcoma, Wilms' tumor and Waldenstrom's macroglobulinemia.
26. A method of treating a human subject having cancer in need of treatment, comprising: An effective amount of the composition according to any one of claims 1 to 21 is administered to the subject.
27. The method of claim 26, wherein: The cancer is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, osteosarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, kidney cancer, multiple myeloma, neuroblastoma, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thymoma, thyroid cancer, transitional cell bladder cancer, uterine sarcoma, Wilms' tumor and Waldenstrom's macroglobulinemia.
28. The method of claim 26, wherein: The method further comprises administering to the subject one or more anticancer agents selected from angiogenesis inhibitors, tyrosine kinase inhibitors, PARP inhibitors, alkylating agents, vinca alkaloids, anthracyclines, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, aromatase inhibitors, mTor inhibitors, retinoids, and HDAC inhibitors.
29. The method of claim 28, wherein: The method further comprises administering to the subject one or more anticancer agents selected from mitoxantrone, topotecan, etoposide, teniposide, bleomycin, actinomycin D, and duocarmycin A.
